Research site

Summerville, South Carolina 29486

1 studies enrolling now · 12 studies all time

What they study most

ASCVD Management, Alzheimer's Disease, Arthritis, Rheumatoid, Asthma, COPD, COVID-19, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, Dyslipidemia, Hypertriglyceridemia, Medical Conditions to be Studied, Moderate to Very Severe COPD

Studies at this site

• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) — Recruiting now
• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis — Completed
• Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. — Completed
• Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States — Completed
• A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis — Completed
• Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab — Completed
• A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) — Completed
• Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo — Completed
• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. — Completed
• A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents — Completed
• Observational Study on Costs and Caregiver Burden in Alzheimer's Disease — Completed
• GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes — Completed